Coagulation activation in young survivors of myocardial infarction (MI) - a population-based case-control study

Summary Formation of an occlusive thrombus by exposure of tissue factor (TF) to circulating blood and subsequent triggering of coagulation by TF-FVIIa complexes on ruptured atherosclerotic plaques is thought to be a key event in acute MI. Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of TF-induced coagulation by neutralizing FXa and inhibiting the TF-FVIIa complex. A case control study was conducted to investigate the role of coagulation activation in MI. Sixty-two patients with verified MI, 40-60 yrs of age, were recruited into the study and examined 1-4 years after the acute coronary event. Thrombinantithrombin complex (TAT) was significantly increased in MI patients (8.2 ± 12.9 µg/l vs. 3.9 ± 2.6 µg/l, p=0.01). In contrast, FVIIa was lower in MI patients (41 ± 13 mU/ml vs. 48 ± 15 mU/ml, p=0.003) accompanied by an increase in plasma free TFPI antigen (20.9 ± 5.0 ng/ml vs. 19.2 ± 4.9 ng/ml, p=0.03). Significant trends for increase in triglycerides and total cholesterol across quartiles of free TFPI Ag were found in both groups, whereas HDL cholesterol decreased across quartiles of TFPI among control subjects. The compensatory increase in plasma free TFPI with established lipid and haemostatic risk factors were abrogated in the MI patients. An apparent increase in the basal activation of the coagulation system was observed in young patients with MI. Enhanced coagulation activation was accompanied by a decrease in FVIIa and increase in free TFPI Ag, probably reflecting a modest triggering of TF-induced coagulation in these patients.

[1]  P. Golino.  The inhibitors of the tissue factor:factor VII pathway. , 2002, Thrombosis research.

[2]  C. Tei,et al.  Imbalance of Plasminogen Activator Inhibitor-I/ Tissue Plasminogen Activator and Tissue Factor/Tissue Factor Pathway Inhibitor in Young Japanese Men with Myocardial Infarction , 2001, Thrombosis and Haemostasis.

[3]  Jacqueline P Mitchell,et al.  Comparison of Novel Hemostatic Factors and Conventional Risk Factors for Prediction of Coronary Heart Disease , 2000, Circulation.

[4]  E. Tremoli,et al.  Tissue factor in atherosclerosis. , 1999, Atherosclerosis.

[5]  How-Ran Guo,et al.  Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. , 1999, Journal of the American College of Cardiology.

[6]  A. Gori,et al.  Elevated Tissue Factor and Tissue Factor Pathway Inhibitor Circulating Levels in Ischaemic Heart Disease Patients , 1998, Thrombosis and Haemostasis.

[7]  J. Hansen,et al.  An enzyme linked immunosorption assay for tissue factor pathway inhibitor. , 1997, Thrombosis research.

[8]  I. Tsuji,et al.  Increased plasma tissue factor levels in acute myocardial infarction. , 1997, American heart journal.

[9]  P. Mannucci,et al.  Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. , 1996, Blood.

[10]  J. Cooper,et al.  Increased Activation of the Haemostatic System in Men at High Risk of Fatal Coronary Heart Disease , 1996, Thrombosis and Haemostasis.

[11]  S. Rapaport,et al.  The Tissue Factor Pathway: How It Has Become a “Prima Ballerina” , 1995, Thrombosis and Haemostasis.

[12]  M. Blombäck,et al.  Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[13]  M. Harada‐Shiba,et al.  Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[14]  D. Ardissino,et al.  Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction , 1994, Circulation.

[15]  J. Hansen,et al.  Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  W. Kisiel,et al.  Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. , 1991, Biochemistry.

[17]  M. L. Larsen,et al.  Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[18]  H. Saito,et al.  Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Rapaport,et al.  Modifications of Extrinsic Pathway Inhibitor (EPI) and Factor Xa that Affect their Ability to Interact and to Inhibit Factor Vila/Tissue Factor: Evidence for a Two-Step Model of Inhibition , 1988, Thrombosis and Haemostasis.

[20]  C. Soria,et al.  Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation. , 1988, Thrombosis research.

[21]  B. Osterud,et al.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[23]  M. Yamagishi,et al.  Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  P. T. Onundarson,et al.  Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. , 1998, Scandinavian cardiovascular journal : SCJ.

[25]  I. Tsuji,et al.  Comparison of plasma tissue factor levels in unstable and stable angina pectoris. , 1998, The American journal of cardiology.

[26]  J. van de Loo.  Circulating factors of the haemostatic systems as indicators of increased or reduced coronary risk. , 1995, British journal of haematology.

[27]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. , 1993, Blood.

[28]  S. Rapaport,et al.  Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.

[30]  James,et al.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. , 1988, Blood.